- Home
- MBAV vs ERAS Comparison
MBAV vs ERAS Comparison
Compare MBAV & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MBAV
- ERAS
- Stock Information
- Founded
- MBAV 2024
- ERAS 2018
- Country
- MBAV United States
- ERAS United States
- Employees
- MBAV N/A
- ERAS N/A
- Industry
- MBAV
- ERAS Biotechnology: Pharmaceutical Preparations
- Sector
- MBAV
- ERAS Health Care
- Exchange
- MBAV NYSE
- ERAS Nasdaq
- Market Cap
- MBAV 368.4M
- ERAS 432.6M
- IPO Year
- MBAV 2024
- ERAS 2021
- Fundamental
- Price
- MBAV $10.25
- ERAS $1.52
- Analyst Decision
- MBAV
- ERAS Strong Buy
- Analyst Count
- MBAV 0
- ERAS 6
- Target Price
- MBAV N/A
- ERAS $4.83
- AVG Volume (30 Days)
- MBAV 13.4K
- ERAS 1.7M
- Earning Date
- MBAV 01-01-0001
- ERAS 03-20-2025
- Dividend Yield
- MBAV N/A
- ERAS N/A
- EPS Growth
- MBAV N/A
- ERAS N/A
- EPS
- MBAV N/A
- ERAS N/A
- Revenue
- MBAV N/A
- ERAS N/A
- Revenue This Year
- MBAV N/A
- ERAS N/A
- Revenue Next Year
- MBAV N/A
- ERAS N/A
- P/E Ratio
- MBAV N/A
- ERAS N/A
- Revenue Growth
- MBAV N/A
- ERAS N/A
- 52 Week Low
- MBAV $9.97
- ERAS $1.23
- 52 Week High
- MBAV $10.53
- ERAS $3.45
- Technical
- Relative Strength Index (RSI)
- MBAV N/A
- ERAS 49.85
- Support Level
- MBAV N/A
- ERAS $1.40
- Resistance Level
- MBAV N/A
- ERAS $1.61
- Average True Range (ATR)
- MBAV 0.00
- ERAS 0.11
- MACD
- MBAV 0.00
- ERAS 0.02
- Stochastic Oscillator
- MBAV 0.00
- ERAS 57.14
About MBAV M3-BRIGADE ACQUISITION V CORP
M3-Brigade Acquisition V Corp is a blank check company.
About ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.